NervGen Pharma Corp
NervGen Pharma Corp is a clinical-stage biotech company focused on developing innovative treatments to enable nervous system repair in cases of traumatic injury and disease. Their lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for spinal cord injury, with additional preclinical evaluations for conditions such as ischemic stroke and amyotrophic lateral sclerosis (ALS). The company is also advancing a new development candidate, NVG-300, in preclinical studies.
NervGen Pharma Corp
112-970 Burrard Street, Unit 1290, Vancouver, BC V6Z 2R4
What We Do
A first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair, currently in a Phase 1b/2a clinical trial for spinal cord injury.
A new development candidate initiated for preclinical evaluation in models of ischemic stroke, ALS, and spinal cord injury.
NervGen is conducting a Phase 1b/2a placebo-controlled proof-of-concept trial for NVG-291 in individuals with spinal cord injury.
Key People
News & Updates
NervGen reported its financial and operational results for the third quarter ended September 30, 2024, including updates on the Phase 1b/2a clinical trial of NVG-291.
NervGen announced that target enrollment of the chronic cohort in its Phase 1b/2a clinical trial for NVG-291 in individuals with spinal cord injury is approaching completion.
NervGen reported its financial and operational results for the second quarter ended June 30, 2024, including advancements in the clinical development of NVG-291 and the initiation of NVG-300.